[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimer39s-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimer39s-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,76,112,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100595024","phase-2-study-to-evaluate-the-efficacy-and-safety-of-kds2010-in-patients-with-alzheimers-disease-with-mild-cognitive-impairment-and-mild-dementia-due-to-alzheimers-disease-100595024",false,"NCT07027072","Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease","Inclusion Criteria:\n\n* Male and female adults aged ≥50 and ≤85 years at the time of written consent\n* Patients with MCI or mild AD confirmed at screening according to the 2024 diagnostic criteria (APPENDIX 1) of the National Institute on Aging-Alzheimer's Association (NIA-AA)\n* Subjects whose total CDR score (CDR-GS) is 0.5 to 1.0 at screening (however, CDR memory score is ≥0.5)\n* Subjects with a Mini-Mental State Examination (MMSE) score of 21 to 30 at screening\n* Subjects who test positive for amyloid on Positron Emission Tomography (PET) during screening\n* Subjects who have a caregiver capable of providing accurate information about the subject's cognitive and functional abilities and appropriate for the planned assessments in the study, as judged by the investigator\n* Subjects (or their legal representatives) who have voluntarily agreed to participate in this study and have given written consent\n\nExclusion Criteria:\n\n* Cognitive impairment or dementia due to causes other than Alzheimer's disease\n\n  * Vascular dementia, central nervous system infections (e.g., HIV, syphilis, etc.), head trauma, Creutzfeldt-Jakob disease, Pick's disease, Huntington's disease, Parkinson's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, thyroid disorders, parathyroid disorders, Vitamin B12 deficiency, folic acid deficiency, other metabolic and nutritional deficiencies, etc.\n  * Alcohol or drug abuse, dependence\n* Subjects with cognitive impairment due to hypothyroidism, nutritional deficiencies, Vitamin B12 or folic acid deficiency as assessed during screening\n* Subjects confirmed during screening to have had the following medical history:\n\n  * Malignant tumors within five years prior to screening except for basal cell carcinoma, cutaneous squamous cell carcinoma, thyroid cancer, or carcinoma in situ that has not recurred in over three years and is considered successfully treated by the investigator\n  * History of alcohol or drug abuse within two years prior to screening\n  * Loss of consciousness of unknown cause, or seizure within the past 52 weeks before screening\n  * Unstable and clinically significant cardiovascular diseases despite appropriate treatment (acute coronary syndrome (ACS), tachycardia, clinically significant arrhythmias, cardiomyopathy, angina of at least CSS III, heart failure of NYHA II-IV, or clinically significant valvular heart disease) within 24 weeks before baseline\n  * Severe or active infectious diseases requiring antibiotics or antivirals within four weeks before baseline\n  * A history of stroke involving a major vascular area, transient ischemic attack (TIA), epilepsy, or severe head trauma with loss of consciousness\n  * Hypersensitivity or allergy to any components of the investigational product\n* Subjects confirmed during screening to have had the following accompanying disease:\n\n  * Clinically significant neurological diseases or serious pathological findings affecting cognitive function as confirmed by brain imaging studies within 52 weeks prior to screening, including multiple sclerosis, normal pressure hydrocephalus, brain tumor (however, exceptions are allowed for lesions diagnosed as benign and with a maximum diameter of less than 1 cm), spinal cord infarction, major hemorrhage (defined as having a diameter \\> 1 cm in MRI) or subdural hemorrhage, cerebral vascular malformation, communicating hydrocephalus, inflammatory demyelinating diseases, etc.\n  * Uncontrolled hypertension despite appropriate treatment at screening or baseline (SBP ≥160 mmHg or DBP ≥100 mmHg)\n  * Dizziness or fainting when standing due to orthostatic hypotension that may affect the evaluation according to the judgment of the investigator\n  * Uncontrolled diabetes (HbA1c \\> 9%) during screening, despite appropriate treatment\n  * Bleeding disorders (Platelet \\\u003C50,000\u002Fmm³) during screening, despite appropriate treatment\n  * Patients with severe hepatic impairment (Child-pugh class C) at screening\n  * Following laboratory test values at screening:\n\n    * AST or ALT \\> 2.5 x ULN\n    * total bilirubin \\> 1.5 x ULN (however, in case of Gilbert syndrome, \\> 3.0 mg\u002FdL)\n    * MDRD eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n  * QTcF interval \\>450 msecs for male or 470 msecs for female(12-lead ECG) during screening\n  * Gastrointestinal diseases that may affect oral administration or absorption (celiac disease, Crohn's disease, intestinal resection, etc.)\n  * Gastrointestinal diseases, including gastric and duodenal ulcers, that may affect the safety evaluation according to the judgment of the investigator\n  * Psychiatric diagnosis or symptoms that may interfere with the study (uncontrolled major depression, uncontrolled schizophrenia, uncontrolled bipolar affective disorder, etc.), as assessed by the investigator\n  * Positive responses to items 4 or 5 on the Columbia University Suicide Severity Rating Scale (C-SSRS) during screening\n  * Other conditions deemed by the investigator to potentially affect the outcome of the study\n* Subjects who have undergone or require treatment with the following:\n\n  * AD disease-modifying agents (aducanumab, lecanemab, donanemab, gantenerumab, solanezumab, blarcamesine, simufilam, tricaprilin, valiltramiprosate, etc.) within 12 weeks before screening\n  * Medications that may improve cognitive abilities or affect AD treatment (AChEIs, donepezil, galantamine, rivastigmine, tacrine, memantine, etc.) within 12 weeks before screening, except if the subject has been on a stable dose for at least 12 weeks before baseline and maintains the same composition\u002Fdosage\u002Fmethod of administration during the study period\n  * CNS-active drugs or those affecting cognitive function antidepressants other than serotonergic drugs \\[e.g., bupropion\\], sedatives \\[e.g., carbamazepine\\], dopamine antagonists \\[e.g., antipsychotics, metoclopramide\\], amfepramone, mazindol) within 12 weeks before screening\n  * Central anticholinergics and sedating H1-antihistamines within 12 weeks before screening.\n\nHowever, exceptions are allowed for one-time use of the drugs, such as second-generation H1 antihistamines (e.g., cetirizine, levocetirizine, etc.) or peripheral anticholinergics with no central action (e.g., trospium for treating overactive bladder). But the use is prohibited for at least 3 days from the date of cognitive function evaluation.\n\n* Other investigational products or clinical trial devices within four weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* Monoamine oxidase inhibitors (MAOIs) and linezolid within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* Opioids (pethidine, tramadol, tapentadol, etc.) within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* Cyclobenzaprine and St. John's wort within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* The following serotonergic drugs within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out),\n\n  * selective serotonin (5HT1) agonists\n  * lithium\n  * lamotrigine\n  * ritonavir\n  * dapoxetine\n  * Selective serotonin reuptake inhibitors (SSRIs)\n  * dapoxetine\n  * Serotonin-norepinephrine reuptake inhibitors (SNRIs)\n  * Tricyclic or tetracyclic antidepressants\n  * triazolopyridine antidepressant However, amitriptyline ≤ 50 mg\u002Fday, trazodone ≤ 100 mg\u002Fday, citalopram ≤ 20 mg\u002Fday, and sertraline ≤ 100 mg\u002Fday are allowed without washout.\n* Use of sympathomimetics (ephedrine, methylphenidate, amphetamine, methamphetamine, lisdexamfetamine, etc.) during the screening period\n* Use of Dextromethorphan during the screening period\n* Use of CYP3A4 strong inducer, CYP3A4 strong inhibitor, CYP2D6 strong inducer, and CYP2D6 strong inhibitor during the screening period\n\n  * Inability to undergo MRI or PET scans\n  * Pregnant or breastfeeding women\n  * Fertile women or men who are unwilling to use effective contraception\\* from the date of written consent until 12 weeks after the last administration of the investigational product\n\n    \\*Effective contraception is defined as follows, and at least one method should be used:\n    * Hormonal contraception (oral, injectable, implantable, etc.)\n    * Intrauterine device (IUD) or system (IUS)\n    * Sterilization or surgical procedures (vasectomy, bilateral tubal ligation\u002Fsurgery, hysterectomy)\n    * Dual contraception methods: Simultaneous use of barrier methods (male condoms) with the methods listed above\n    * Absolute abstinence: Total abstinence from sexual intercourse is recognized if the investigator deems the subject's age, occupation, lifestyle, or sexual orientation assures contraception. However, periodic abstinence (calendar method, mucus method, and symptothermal method), withdrawal, and coitus interruptus are not recognized as effective contraception methods.\n  * Other conditions deemed by the investigator to be unsuitable for participation in the study","ALL","50 Years","85 Years",{"count":20,"type":21},114,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A randomized, double-blind, placebo-controlled, dose-finding Phase 2a clinical trial will be conducted to evaluate the efficacy and safety of KDS2010 in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild dementia due to Alzheimer's disease.\n\nBased on preliminary efficacy observed in the Phase 1 clinical trial, a clinical trial will be conducted in Korea. Eligible patients diagnosed with MCI or mild Alzheimer's disease will be stratified by disease stage (MCI\u002Fmild AD) prior to randomization. Subjects will be randomly assigned in a 1:1:1 ratio to either Treatment Group 1, Treatment Group 2, or the Control Group. The investigational product will be administered orally once daily for a duration of 24 weeks. Approximately 114 subjects will be enrolled, including an estimated 20% dropout rate, with 38 subjects assigned to each group (Treatment Group 1, Treatment Group 2, and Control Group).\n\nThe objectives of the study are as follows:\n\n1. Efficacy Objectives: Efficacy will be evaluated through changes in cognitive function, self-management, and daily living activities before and after administration of KDS2010. Biomarker analysis in plasma and in cerebrospinal fluid (CSF; optional) will also be conducted to explore treatment efficacy.\n2. Safety Objectives: The safety and tolerability will be evaluated after administration of KDS2010.\n3. Exploratory Objectives: The efficacy of Treatment Groups 1 and 2 compared to the Control group will be explored through cognitive endpoints (the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), and the Mini-Mental State Examination (MMSE)), stratified by demographic information, tauopathy, and ApoE4 genes.\n\nBased on nonclinical and Phase 1 clinical data, KDS2010 will be administered orally once daily at two dose levels: 60 mg and 120 mg.",[27,28,29],"Mild Cognitive Impairment (MCI)","Mild Dementia","Alzheimer's Disease",[31,28,32,33,29],"Mild Cognitive Impairment","KDS2010","MAO-B inhibitor","RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":38},"2025-08-06",{"date":42,"type":21},"2027-12-31",{"name":44,"class":45},"NeuroBiogen Co., Ltd","INDUSTRY",8,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100608703","evaluation-of-the-link-between-carotid-arterial-wall-viscosity-and-major-neurocognitive-disorders-100608703","NCT07205003","Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders","Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders of Vascular Origin or Linked to Alzheimer's Disease","VISCOG","Inclusion Criteria:\n\n* Age over 70\n* Memory consultation consultant (neurology or geriatrics)\n* Brain MRI less than one year old or planned as part of the cognitive assessment performed.\n* Patient diagnosed with Alzheimer's disease according to DSM-5 criteria or vascular dementia according to DSM-5 criteria, or presenting a memory complaint without evidence of a dementia-related condition.\n* No objection from the patient or their caregiver.\n* Patient covered by a health insurance plan\n\nExclusion Criteria:\n\n* Known unilateral or bilateral carotid stenosis or history of carotid surgery\n* Permanent CA\u002FAF\n* Patient presenting with confusion\n* Known psychiatric illness (severe depression, psychosis, etc.)\n* Non-vascular, non-Alzheimer's dementia (e.g., Lewy Body Dementia, Parkinsonian Dementia, Progressive Supranuclear Palsy)\n* Refusal to participate\n* MMS less than or equal to 10\n* Contraindication to performing an MRI\n* Any acute decompensated pathology\n* Patient under guardianship or curatorship","70 Years",{"count":57,"type":21},140,"1 Day","OBSERVATIONAL","The mechanical behavior of conductance arteries is viscoelastic. While the elastic component has been extensively studied, the viscous component has often been neglected for methodological reasons and also because it was considered weak.\n\nUnlike a purely elastic solid, which exhibits instantaneous deformation\u002Frelaxation upon application\u002Fdiscontinuation of a force, a viscoelastic solid is characterized, from a mechanical point of view, by a delay between the application or discontinuation of the force and deformation. Thus, at the arterial level, the elasticity of the arterial wall allows the internal diameter to increase proportionally to the blood pressure during systole. The viscous component will induce a delay in diameter restoration, resulting in a larger diameter at each pressure level during the diastolic phase compared to the systolic phase. This results in a shift between the systolic and diastolic curves of the pressure-diameter relationship, creating a hysteresis loop. From a thermodynamic point of view, while a purely elastic material fully restores the energy stored during the loading phase, viscoelastic arteries will incompletely restore this energy. Thus, the surface of the hysteresis loop reflects the energy dissipated during each cardiac cycle (WV), and the area under the loading phase curve represents the energy stored by the arterial wall (WE) during the latter. Thus, arterial wall viscosity (APV) can be expressed either as the absolute value of WV or as a function of the stored energy (WV\u002FWE). Physiologically, this energy loss is low. Its increase could be accompanied by excessive energy dissipation, leading to increased cardiac work and cardio-circulatory decoupling. Conversely, low parietal viscosity could lead to damage to peripheral organs by excessive transmission of pulsatile energy to the periphery due to lack of damping.",[62,29],"Neurocognitive Disorders",[64],"carotid arterial wall viscosity","2026-05-21",{"date":67,"type":38},"2026-05-22",{"date":69,"type":38},"2022-02-15",{"date":71,"type":21},"2028-05-15",{"name":73,"class":74},"University Hospital, Rouen","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":75},"100590257","cervical-lymphatico-venous-bypass-for-treatment-of-alzheimers-disease---proof-of-concept-study-clyveb-ad-1-study-100590257","NCT06965062","Cervical Lymphatico-Venous Bypass for Treatment of Alzheimer's Disease - Proof of Concept Study (CLyVeB-AD-1 Study)","CLyVeB-AD-1","Inclusion Criteria:\n\n* Diagnosis of mild-moderate Alzheimer's disease (based on NIA-AA criteria);\n* Mini-Mental State Examination (MMSE) score 10-22;\n* Both participants and caregiver are able to understand English or Mandarin\n* Ability to provide informed consent or have a legally authorised representative to provide informed consent;\n* Good family support for post-treatment care and rehabilitation;\n* Fit for general anaesthesia\u002Fdeep sedation and surgery (ASA 1-2; excluding the diagnosis of Alzheimer's Disease).\n\nExclusion Criteria:\n\n* Cognitive decline due to prior infection or autoimmune diseases;\n* History of major cerebrovascular events or significant cardiovascular diseases;\n* Inability to have the head turned passively by at least 40 degrees;\n* Previous neck lymph node surgery or irradiation;\n* Active infection or malignancy;\n* Any contraindications to surgery or lumbar puncture\n* Any contraindication to MRI\u002FPET scan (eg. metallic implant that are not MRI-safe, known radiotracer allergy)\n* Experimental Alzheimer's Disease treatment within the past 6 months. • Current use of monoclonal antibodies treatment (eg. lecanemab\u002Fdonanemab)","80 Years",{"count":85,"type":21},10,[87],"NA","Alzheimer's disease (AD), one of the most common causes of dementia in Singapore and the developed world, is a neurodegenerative disorder with high socioeconomic impact. Accumulation of neurotoxic proteins (ie. amyloid, tau) are purported to lead to neuroinflammation, synaptic dysfunction and cognitive decline. The available pharmacotherapy provide limited symptomatic control, modest effect on disease progression with significant risk of side effects. Patients with AD eventually run out of effective pharmacotherapy and deteriorate.\n\nRecent evidence implicated the glymphatic system, meningeal lymphatics of the brain, and downstream drainage to the cervical lymphatic system in the accumulation of neurotoxic proteins in AD. This presented the opportunity for extra-cranial intervention, and has since been demonstrated in preclinical models. Based on these development, Xie and colleagues pioneered the deep cervical lymph node to venous bypass (DCLNV-BP) procedure with very promising early outcomes. The observed improvement had been attributed to enhanced clearance of the neurotoxic proteins. Knowledge gap and clinical equipoise remain, and clinical trials are required to understand the safety, mechanism of action, patient selection, and long-term outcomes.\n\nIn this proof of concept study, the investigators aim to assess safety and preliminary efficacy of DCLNV-BP in AD. An approach using objective clinical assessments, biomarkers and neuroimaging, to assess safety, evaluate preliminary efficacy and elucidate the possible mechanism underlying the observed effects, is undertaken. Since there are limited effective treatment for AD, this procedure is potentially ground breaking if it proves to halt progression or even improve patients' cognition, function and behaviour. Indirectly, this will have enormous health economic benefit for Singapore and the developed world that is facing the silver tsunami. Findings from this pilot study will lay the groundwork for future trials and research collaboration in AD and other neurodegenerative diseases.",[90,91,92,29,93],"Alzheimer Disease","Dementia Alzheimer Type","Dementia Alzheimer's Type","Alzheimer's Disease (AD)",[95,96,97,98,99,100,101,102],"Alzheimer's Disease","Dementia","lymphatic surgery","lymphaticovenous anastomosis","lymphaticovenous bypass","cervical lymph node","meningeal lymphatic system","glymphatic system","2026-01-11",{"date":105,"type":38},"2026-01-13",{"date":107,"type":38},"2025-04-01",{"date":109,"type":21},"2030-03-31",{"name":111,"class":74},"Vincent Tay Khwee Soon",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":75},"100583093","the-clinical-study-of-synaptic-plasticity-based-lencanumab-for-the-treatment-of-early-alzheimers-disease-100583093","NCT06871839","The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease","Inclusion Criteria:\n\n1. Age between 50 and 90 years.\n2. Male or female patients.\n3. Patients with MCI and mild AD.\n4. MMSE score ≥20, CDR overall score of 0.5 or 1.\n5. Amyloid-positive confirmed by Amyloid-PET or CSF.\n6. Have a reliable caregiver to accompany the patient during study visits and supervise the use of study medication during the trial.\n7. Agree to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with cognitive impairment due to reasons other than AD.\n2. A history of transient ischemic attack (TIA), stroke, cerebral hemorrhage, or seizure within the 12 months prior to screening.\n3. A score of \\>17 on the Hamilton Depression Scale at screening, or any suicidal behavior within 6 months prior to screening, at screening, or at the baseline visit, as well as any psychiatric diagnosis or symptoms that interfere with the study procedure (such as hallucinations, anxiety disorder, or paranoia).\n4. Patients with a bleeding disorder or receiving anticoagulant therapy, as well as any with malignant tumors, severe gastrointestinal, kidney, liver, respiratory, immune, endocrine, and cardiovascular system diseases that affect this study.\n5. A hypersensitivity reaction to ranucimab or any other ingredient in the injection solution, or to any monoclonal antibody treatment.\n6. Contraindications to MRI scanning, including those with a pacemaker\u002Fdefibrillator or ferromagnetic metal implants (except for skull and cardiac devices approved as safe for MRI scanning).\n7. A known or suspected history of drug or alcohol abuse or dependence within the 2 years prior to screening.\n8. Participation in a clinical study involving any therapeutic monoclonal antibody or novel compounds for the treatment of AD within the 6 months prior to screening, unless it can be proven that the subject was in the placebo treatment group.\n9. Planning to undergo surgery requiring general anesthesia during the study period.\n10. A positive pregnancy test result, lactation, or pregnancy in females at screening or baseline.","90 Years",{"count":120,"type":21},120,"Alzheimer's disease (AD) manifests itself in cognitive decline, impaired ability to perform daily life, and a variety of behavioral and psychiatric symptoms, seriously endangering the health of the elderly. The prevalence and disability rates of AD in China remain high, and the lack of effective treatment options has brought a heavy burden to patients and their families. Early intervention is regarded as an effective strategy to improve clinical symptoms, delay disease progression and maintain current quality of life. The humanized monoclonal antibody lencanemab (Lecanemab) was approved by the U.S. FDA in July 2023 for the treatment of mild cognitive impairment or mild dementia caused by AD, and was officially approved in January 2024 in China. Lencanemab highly targets soluble and insoluble neurotoxic β-amyloid (Aβ) proteins, reducing pathogenic Aβ plaque deposition and preventing its formation in the brains of AD patients, thus reducing neurotoxicity and improving patients' cognitive functions. In addition, lencanumab may also play a neuroprotective role by modulating synaptic plasticity and regulating neural network activity in brain neurons. However, there is a lack of clinical studies to prove this mechanism. In this study, we will enroll consecutive patients with early AD treated with lencanemab infusion as well as those receiving conventional anti-dementia therapy, and comprehensively assess the effects and intrinsic molecular mechanisms of lencanemab on synaptic function and neural networks using magnetic resonance imaging, molecular imaging positron emission tomography (PET), neuropsychological assessment, and analysis of blood cerebrospinal fluid samples.",[29,123,124],"Lecanemab","Functional Magnetic Resonance Imaging",[126,123,127],"Alzheimer's disease","functional magnetic resonance imaging","2025-07-19",{"date":130,"type":38},"2025-07-22",{"date":132,"type":38},"2025-03-10",{"date":134,"type":21},"2026-12-31",{"name":136,"class":74},"Cuibai Wei，Clinical Professor",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":155,"locationsCount":4},"100579745","rivastigmine-mini-tablet-for-alzheimers-disease-100579745","NCT06828289","Rivastigmine Mini-Tablet for Alzheimer's Disease","Observational Study of Rivastigmine Mini-Tablet in Patients with Alzheimer's Disease","Inclusion Criteria:\n\n* Age 50 or older\n* Meet the National Institute of Aging-Alzheimer's Association clinical criteria for probable Alzheimer's disease\n* Have a Mini-Mental State Examination score of 10 to 24 at Screening and Baseline\n* Geriatric Depression Scale score \\\u003C=7 at Screening\n* Hachinski Ischemic Scale \\\u003C=4 at Screening\n* Brain MRI should meet: no infarcts in key areas (thalamus, hippocampus, entorhinal cortex, perirhinal cortex, angular gyrus, etc.), ≤ 2 stroke lesions \\> 1.5 cm in diameter, and Fazekas Scale - assessed white matter lesion grade\n\n  * 2\\.\n* Patients whose caregivers are well-informed about the patients' condition and, if possible, live with them.\n* Provide written informed consent\n\nExclusion Criteria:\n\n* Any systemic or neurological condition that could contribute to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease\n* Any psychiatric diagnosis or symptoms (hallucinations, major depression, delusions, etc) interfering with study procedures\n* An advanced, severe or unstable disease of any type (cardiac, respiratory, gastrointestinal, renal disease, etc) that may interfere with efficacy evaluations\n* Subjects treated with medication for dementia two weeks prior to baseline",{"count":145,"type":21},1000,"The objective of this study is to evaluate the efficacy and safety of rivastigmine mini-tablets in individuals diagnosed with mild to moderate Alzheimer's disease (AD).",[29],"NOT_YET_RECRUITING","2025-02-18",{"date":151,"type":38},"2025-02-20",{"date":153,"type":21},"2025-02-28",{"date":134,"type":21},{"name":156,"class":74},"Peking University First Hospital"]